AUTHORS
Musa Yilmaz, MD, Tapan Kadia I, MD2, Nicholas Short, MD3, Courtney DiNardo, MD, MSCE4, Cara Cooper5, Gautam Borthakur, MD6, Naveen Pemmaraju, MD7, Yesid Alvarado Valero, MD8, Joseph Jabbour9, Fadi G. Haddad, MD10, Kelly Sharon Chien, MD11, Wei Ying Jen, BM BCh, FRCPath12, Alexandre Bazinet, MD, MSc13, Sanam Loghavi, MD14, Elias Jabbour, MD15, Steven Kornblau, MD16, Michael Andreeff, MD, PhD17, Farhad Ravandi, MD18, Hagop Kantarjian, MD19, Guillermo Garcia-Manero, MD20, Naval Daver, MD21
AFFILIATIONS
1 UT MD Anderson Cancer Center, Houston, Texas, United States
2 UT MD Anderson Cancer Center, Houston, Texas, United States
3 UT MD Anderson Cancer Center, Houston, Texas, United States
4 UT MD Anderson Cancer Center, Houston, Texas, United States
5 UT MD Anderson Cancer Center, Houston, Texas, United States
6 UT MD Anderson Cancer Center, Houston, Texas, United States
7 UT MD Anderson Cancer Center, Houston, Texas, United States
8 UT MD Anderson Cancer Center, Houston, Texas, United States
9 UT MD Anderson Cancer Center, Houston, Texas, United States
10 UT MD Anderson Cancer Center, Houston, Texas, United States
11 UT MD Anderson Cancer Center, Houston, Texas, United States
12 UT MD Anderson Cancer Center, Houston, Texas, United States
13 UT MD Anderson Cancer Center, Houston, Texas, United States
14 UT MD Anderson Cancer Center, Houston, Texas, United States
15 UT MD Anderson Cancer Center, Houston, Texas, United States
16 UT MD Anderson Cancer Center, Houston, Texas, United States
17 UT MD Anderson Cancer Center, Houston, Texas, United States
18 UT MD Anderson Cancer Center, Houston, Texas, United States
19 UT MD Anderson Cancer Center, Houston, Texas, United States
20 UT MD Anderson Cancer Center, Houston, Texas, United States
21 UT MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background: Quizartinib, a potent and selective FLT3 inhibitor, demonstrated clinical efficacy in both FLT3-ITD mutated and FLT3 wild-type (WT) acute myeloid leukemia (AML). In the QuANTUM-First and QUIWI randomized clinical trials, the addition of quizartinib to standard induction and consolidation chemotherapy improved survival in newly diagnosed patients with FLT3-ITD mutated or WT AML.
Aims: To evaluate the safety and efficacy of quizartinib plus cladribine, idarubicin, and cytarabine (CLIA) in ND and relapsed/refractory (R/R) FLT3-ITD mutated and WT AML.
Methods: Eligible pts were <75 years, ECOG ≤2, fit for intensive chemotherapy, creatinine and bilirubin <1.5 mg/dL, and LVEF ≥50%. Phase 1 evaluated quizartinib 17.7 and 26.5 mg on days 6-19 of induction and 4-28 of consolidation with CLIA. Consolidation (≤5 cycles) used CLIA plus quizartinib. The CLIA regimen included induction with cladribine 5 mg/m² (days 1–5), cytarabine 1.5 g/m² (days 1–5), and idarubicin 10 mg/m² (days 1–3). Consolidation (up to 5 total cycles) included cladribine 5 mg/m² (days 1–3), cytarabine 1 g/m² (days 1–3), and idarubicin 8 mg/m² (days 1–2).
Results: A total of 47 patients were treated: 17 in phase 1 and 30 in phase 2. No dose-limiting toxicities (DLTs) were observed in 3 patients treated at the 17.7 mg dose level. One DLT (myocarditis/pericarditis) was observed at 26.5 mg, which was selected as the recommended phase 2 dose.
ND FLT3-ITD-mutated cohort (N=15): Median age was 38 years (22-60); 80% had diploid karyotype, median FLT3-ITD VAF 29% (1-54%); ELN 2022 risk was intermediate in 80% and high in 20%. Baseline mutations (>15%) included NPM1 (47%), DNMT3A (27%), IDH1/2 (20%), and WT1 (20%). CR/CRi, EOC1 MFC MRD negativity (0.01%), and FLT3-NGS negativity (5×10⁻⁵) were 93%, 92% (12/13), and 40% (4/10), respectively. Best MRD negativity was 100% by MFC (11/11) and FLT3-NGS (10/10). Among NPM1-mutated pts, NPM1-NGS MRD negativity at EOC1 and best response was 0% (0/6) and 100%, respectively. Pts received a median of 2 cycles (1-3). Median time to ANC ≥1000 and platelets >100K was 28 (22-34) and 24 (20-61) days. At last follow-up, 8 (53%) underwent allo-SCT, 3 switched therapy, 3 transferred care, and 1 was lost to follow-up. After a median follow-up of 11 months, no relapses or deaths occurred.
R/R FLT3-ITD-mutated cohort (N=17): Median age was 52 years (23-72), median prior therapies 3 (1-7), and 71% had received a prior FLT3 inhibitor. ELN adverse risk was present in 67%. Common co-mutations (>15%) were WT1 (41%), DNMT3A (35%), NPM1 (29%), RUNX1 (23%), and BCOR (18%). CR/CRi and MLFS rates were 42% and 18%. Best MRD negativity was 66% (2/3) by MFC and 50% (1/2) by FLT3-NGS. Of 10 responders, 7 underwent allo-SCT (3 relapsed, 3 remained in remission, 1 died in CR); both responders without SCT relapsed. Median follow-up was 18 months and median OS 5.7 months.
ND and R/R FLT3-ITD negative cohorts (N=15): Four ND and 11 R/R pts were treated. Median age was 39 years (22-71); 93% had ELN adverse-risk disease. Common mutations (>15%) were RUNX1 (33%), WT1 (33%), TP53 (20%), and NRAS (20%). Three of 4 ND pts (75%) responded (2 CR, 1 PR); the non-responder had secondary AML after HMA/venetoclax for CMML. All responders underwent allo-SCT in CR1. In R/R disease, median prior therapies were 3 (1-8), ORR was 27% (2 MLFS, 1 CRi), and 2 responders underwent allo-SCT. Median OS was 66 and 6.2 months in ND and R/R cohorts, respectively.
In ND pts, the most common non-hematological adverse events (regardless of causality) were infectious and febrile neutropenias, with 48 events, including 26 (54%) grade ≥3. Gastrointestinal and hepatobiliary toxicities were the second most common, with 46 events, including 5 (11%) grade ≥3, followed by electrolyte abnormalities with 19 events, including 3 (16%) grade ≥3. In the R/R cohort, infectious and febrile neutropenias were also the most common adverse events, with 110 events, including 65 (59%) grade ≥3. Gastrointestinal toxicities were the second most common, with 63 events, including 6 (10%) grade ≥3, followed by electrolyte abnormalities with 39 events, including 8 (21%) grade ≥3.
Conclusions: In newly diagnosed FLT3-ITD–mutated patients, responses were deep and durable with high MRD negativity rates and no relapses or deaths observed at current follow-up. While outcomes in the R/R setting remained limited, a subset achieved meaningful responses, enabling a successful bridge to transplantation.
DISCLOSURES
Musa Yilmaz, MD: Curio Science - Honoraria; Daiichi Sankyo - Research Funding; Cardinal Health - Consultancy (Includes expert testimony); Daiichi Sankyo - Consultancy (Includes expert testimony)